## **Eivind Hovig**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6751476/publications.pdf

Version: 2024-02-01

254 papers 12,496 citations

<sup>38742</sup> 50 h-index

30922 102 g-index

284 all docs

284 docs citations

times ranked

284

17266 citing authors

#	Article	IF	CITATIONS
1	MirGeneDB 2.1: toward a complete sampling of all major animal phyla. Nucleic Acids Research, 2022, 50, D204-D210.	14.5	63
2	A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer. NAR Cancer, 2022, 4, zcab051.	3.1	5
3	A national precision cancer medicine implementation initiative for Norway. Nature Medicine, 2022, 28, 885-887.	30.7	7
4	Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine, 2022, 20, 225.	4.4	7
5	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia, 2022, 36, 1887-1897.	7.2	23
6	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative Journal of Clinical Oncology, 2022, 40, e13634-e13634.	1.6	2
7	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	5.1	9
8	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	2.4	28
9	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. Journal of Personalized Medicine, 2021, 11, 330.	2.5	1
10	Recommendations for the FAIRification of genomic track metadata. F1000Research, 2021, 10, 268.	1.6	7
11	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	2.8	11
12	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. Frontiers in Immunology, 2021, 12, 663865.	4.8	17
13	The genetic structure of Norway. European Journal of Human Genetics, 2021, 29, 1710-1718.	2.8	10
14	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
15	Cancer Predisposition Sequencing Reporter ( <scp>CPSR</scp> ): A flexible variant report engine for highâ€throughput germline screening in cancer. International Journal of Cancer, 2021, 149, 1955-1960.	5.1	12
16	The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants. BMC Cancer, 2021, 21, 930.	2.6	22
17	382â€The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma. , 2021, 9, A416-A416.		0
18	MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Research, 2020, 48, D132-D141.	14.5	194

#	Article	IF	CITATIONS
19	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	2.4	365
20	Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates, 2020, 48, 100662.	14.4	42
21	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. Journal of Clinical Medicine, 2020, 9, 2290.	2.4	12
22	Breast cancer survival in Nordic BRCA2 mutation carriersâ€"unconventional association with oestrogen receptor status. British Journal of Cancer, 2020, 123, 1608-1615.	6.4	8
23	Accuracy and efficiency of germline variant calling pipelines for human genome data. Scientific Reports, 2020, 10, 20222.	3.3	61
24	Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series. Blood Advances, 2020, 4, 1859-1866.	5 <b>.</b> 2	7
25	Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study. Acta Oncológica, 2020, 59, 733-740.	1.8	8
26	Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes. Cancers, 2020, 12, 1719.	3.7	7
27	Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Communications Biology, 2020, 3, 196.	4.4	27
28	Editorial: Genomic Colocalization and Enrichment Analyses. Frontiers in Genetics, 2020, 11, 617876.	2.3	0
29	Loss of Snord116 impacts lateral hypothalamus, sleep, and food-related behaviors. JCI Insight, 2020, 5, .	5.0	19
30	A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update Journal of Clinical Oncology, 2020, 38, 62-62.	1.6	2
31	The ELIXIR Human Copy Number Variations Community: building bioinformatics infrastructure for research. F1000Research, 2020, 9, 1229.	1.6	5
32	Abstract A31: Tracking the evolution of soft tissue sarcoma and GIST using liquid biopsies. , 2020, , .		0
33	A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres/registries. European Journal of Cancer, 2019, 119, 112-121.	2.8	13
34	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	1.5	27
35	Colocalization analyses of genomic elements: approaches, recommendations and challenges. Bioinformatics, 2019, 35, 1615-1624.	4.1	53
36	Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications, 2019, 10, 2674.	12.8	240

#	Article	IF	CITATIONS
37	Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. Journal of Physical Education and Sports Management, 2019, 5, a003566.	1.2	6
38	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	1.5	42
39	Roadmap for a precision-medicine initiative in the Nordic region. Nature Genetics, 2019, 51, 924-930.	21.4	22
40	Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift. Cancers, $2019$ , $11$ , $132$ .	3.7	7
41	Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer Immunology Research, 2019, 7, 701-706.	3.4	8
42	Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries. Frontiers in Immunology, 2019, 10, 2796.	4.8	9
43	PathTracer: High-sensitivity detection of differential pathway activity in tumours. Scientific Reports, 2019, 9, 16332.	3.3	2
44	Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Scientific Reports, 2019, 9, 18555.	3.3	13
45	Genetic Variation/Evolution and Differential Host Responses Resulting from In-Patient Adaptation of <i>Mycobacterium avium</i> . Infection and Immunity, 2019, 87, .	2.2	9
46	From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America. International Journal of Cancer, 2019, 145, 318-326.	5.1	14
47	Physical 3D Modeling of Whole Genomes: Exploring Chromosomal Organization Properties and Principles., 2019,, 331-360.		0
48	Deep Profiling of Genetic Aberrations and Clonal Evolution in Follicular Lymphoma. Blood, 2019, 134, 20-20.	1.4	0
49	Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling. Blood, 2019, 134, 1497-1497.	1.4	0
50	Personal Cancer Genome Reporter: variant interpretation report for precision oncology. Bioinformatics, 2018, 34, 1778-1780.	4.1	33
51	Sample-Index Misassignment Impacts Tumour Exome Sequencing. Scientific Reports, 2018, 8, 5307.	3.3	17
52	Potentially pathogenic germline CHEK2 c.319+2T> A among multiple early-onset cancer families. Familial Cancer, 2018, 17, 141-153.	1.9	12
53	Cancer risk and survival in $\langle i \rangle$ path_MMR $\langle i \rangle$ carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	12.1	410
54	Our genes, our selves: hereditary breast cancer and biological citizenship in Norway. Medicine, Health Care and Philosophy, 2018, 21, 239-242.	1.8	2

#	Article	IF	CITATIONS
55	Filesystem Front-end for Seamless Job Management in Sensitive Data e-Infrastructures and Cloud Federation. , $2018, $ , .		0
56	PO4.80 Diagnostic potential of the IgM igOme (IgM repertoire) biomarkers for brain tumors. Neuro-Oncology, 2018, 20, iii298-iii299.	1.2	0
57	Ancient genomes from Iceland reveal the making of a human population. Science, 2018, 360, 1028-1032.	12.6	62
58	Patterns of genomic evolution in advanced melanoma. Nature Communications, 2018, 9, 2665.	12.8	62
59	Identification of genetic variants for clinical management of familial colorectal tumors. BMC Medical Genetics, 2018, 19, 26.	2.1	18
60	Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. Hereditary Cancer in Clinical Practice, 2018, 16, 4.	1.5	7
61	The Prospective Lynch Syndrome Database. , 2018, , 461-468.		2
62	Abstract A101: The MetAction trial: long-lasting responses to molecularly matched therapy in end-stage cancer. , 2018, , .		1
63	Norwegian e-Infrastructure for Life Sciences (NeLS). F1000Research, 2018, 7, 968.	1.6	10
64	Abstract A08: Disease monitoring by liquid biopsies in sarcomas. , 2018, , .		0
65	Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse. Blood, 2018, 132, 3157-3157.	1.4	0
66	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	12.1	411
67	Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. BMC Cancer, 2017, 17, 29.	2.6	21
68	GSuite HyperBrowser: integrative analysis of dataset collections across the genome and epigenome. GigaScience, 2017, 6, 1-12.	6.4	22
69	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	12.1	127
70	High number of kinomeâ€mutations in nonâ€small cell lung cancer is associated with reduced immune response and poor relapseâ€free survival. International Journal of Cancer, 2017, 141, 184-190.	5.1	14
71	Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open, 2017, 2, e000158.	4.5	8
72	The rainfall plot: its motivation, characteristics and pitfalls. BMC Bioinformatics, 2017, 18, 264.	2.6	5

#	Article	IF	Citations
73	P1.02-028 Pathways Involved in Early Stage Lung Cancers. Journal of Thoracic Oncology, 2017, 12, S1934-S1935.	1.1	О
74	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Current Pharmaceutical Design, 2017, 23, 4716-4725.	1.9	11
75	Reply to Towfic and others' letter to the editor. Biostatistics, 2017, 18, 586-587.	1.5	2
76	HPV Genotyping of Modified General Primer-Amplicons Is More Analytically Sensitive and Specific by Sequencing than by Hybridization. PLoS ONE, 2017, 12, e0169074.	2.5	9
77	A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America. BMC Cancer, 2017, 17, 623.	2.6	40
78	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	1.5	49
79	Genome build information is an essential part of genomic track files. Genome Biology, 2017, 18, 175.	8.8	6
80	Abstract 3432: microRNA expression reflects site specificity of metastatic colorectal cancer., 2017,,.		1
81	The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice Journal of Clinical Oncology, 2017, 35, e14033-e14033.	1.6	0
82	Abstract 5700: CircSarc: Disease monitoring by liquid biopsies in sarcomas., 2017,,.		0
83	TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. Frontiers in Genetics, 2016, 07, 85.	2.3	76
84	Transcriptomic Profiling of Tumor Aggressiveness in Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms. Pancreas, 2016, 45, 1196-1203.	1.1	7
85	Subtypeâ€specific microâ€RNA expression signatures in breast cancer progression. International Journal of Cancer, 2016, 139, 1117-1128.	5.1	53
86	Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics, 2016, 17, 263.	2.6	26
87	Hi-C-constrained physical models of human chromosomes recover functionally-related properties of genome organization. Scientific Reports, 2016, 6, 35985.	3.3	72
88	Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology, 2016, 196, 1400-1411.	0.8	35
89	Galaxy Portal: interacting with the galaxy platform through mobile devices. Bioinformatics, 2016, 32, 1743-1745.	4.1	5
90	Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study. Tumor Biology, 2016, 37, 11065-11072.	1.8	7

#	Article	IF	CITATIONS
91	Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses. Biostatistics, 2016, 17, 29-39.	1.5	268
92	MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Oncotarget, 2016, 7, 55128-55140.	1.8	11
93	Multilayer Modeling of Skin Color and Translucency. , 2016, , 27-48.		1
94	Ten modifiers of BRCA1 penetrance validated in a Norwegian series. Hereditary Cancer in Clinical Practice, 2015, 13, 14.	1.5	2
95	Automated amplicon design suitable for analysis of DNA variants by melting techniques. BMC Research Notes, 2015, 8, 667.	1.4	6
96	ClusTrack: Feature Extraction and Similarity Measures for Clustering of Genome-Wide Data Sets. PLoS ONE, 2015, 10, e0123261.	2.5	3
97	c-Myb Binding Sites in Haematopoietic Chromatin Landscapes. PLoS ONE, 2015, 10, e0133280.	2.5	20
98	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001.	12.8	266
99			

#	Article	IF	CITATIONS
109	A statistical model of ChIA-PET data for accurate detection of chromatin 3D interactions. Nucleic Acids Research, 2014, 42, e143-e143.	14.5	50
110	HiBrowse: multi-purpose statistical analysis of genome-wide chromatin 3D organization. Bioinformatics, 2014, 30, 1620-1622.	4.1	37
111	From proteomes to complexomes in the era of systems biology. Proteomics, 2014, 14, 24-41.	2.2	35
112	Performance comparison of four exome capture systems for deep sequencing. BMC Genomics, 2014, 15, 449.	2.8	152
113	Identifying pathogenic processes by integrating microarray data with prior knowledge. BMC Bioinformatics, 2014, 15, 115.	2.6	2
114	Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience, 2014, 1, 82-94.	2.2	39
115	Mutations in NSCLC Journal of Clinical Oncology, 2014, 32, e18516-e18516.	1.6	0
116	Abstract 4876: Characterization of malignant melanoma growth triggered by the brain microenvironment in experimental metastasis models. , 2014, , .		0
117	Abstract 370: Modeling signaling networks in tumor immunology. , 2014, , .		0
118	Abstract 2850: Biomarkers for detection of exfoliated tumor cells in the peritoneal cavity in rectal cancer. , $2014$ , , .		0
119	Abstract 4197: Regulators of p21 transcription in melanoma. , 2014, , .		0
120	Pathway analysis of genetic markers associated with a functional MRI faces paradigm implicates polymorphisms in calcium responsive pathways. NeuroImage, 2013, 70, 143-149.	4.2	13
121	Light-Controlled Modulation of Gene Expression Using Polyamidoamine Formulations. Nucleic Acid Therapeutics, 2013, 23, 160-165.	3.6	10
122	Light-Induced mRNA Transfection. Methods in Molecular Biology, 2013, 969, 89-100.	0.9	0
123	Substantial Loss of Conserved and Gain of Novel MicroRNA Families in Flatworms. Molecular Biology and Evolution, 2013, 30, 2619-2628.	8.9	84
124	The Genomic HyperBrowser: an analysis web server for genome-scale data. Nucleic Acids Research, 2013, 41, W133-W141.	14.5	32
125	Ten Simple Rules for Reproducible Computational Research. PLoS Computational Biology, 2013, 9, e1003285.	3.2	509
126	Predicting Physical Interactions between Protein Complexes. Molecular and Cellular Proteomics, 2013, 12, 1723-1734.	3.8	21

#	Article	IF	Citations
127	Handling realistic assumptions in hypothesis testing of 3D co-localization of genomic elements. Nucleic Acids Research, 2013, 41, 5164-5174.	14.5	22
128	Evaluation of Biodegradable Peptide Carriers for Light-Directed Targeting. Nucleic Acid Therapeutics, 2013, 23, 131-139.	3.6	6
129	Enhancing nucleic acid delivery by photochemical internalization. Therapeutic Delivery, 2013, 4, 1125-1140.	2.2	17
130	Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer. PLoS ONE, 2013, 8, e66165.	2.5	132
131	Abstract C31: Characterization of malignant melanoma growth triggered by the brain microenvironment in experimental metastasis models. , 2013, , .		0
132	Potent Gene Silencing In Vitro at Physiological pH Using Chitosan Polymers. Nucleic Acid Therapeutics, 2012, 22, 96-102.	3.6	5
133	Towards a quantitative understanding of the MITF-PIAS3-STAT3 connection. BMC Systems Biology, 2012, 6, $11.$	3.0	5
134	Performance Comparison of Multiple Microarray Platforms for Gene Expression Profiling. Methods in Molecular Biology, 2012, 802, 141-155.	0.9	13
135	Increased expression of IRF4 and ETS1 in CD4 <sup>+</sup> cells from patients with intermittent allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 33-40.	5 <b>.</b> 7	25
136	A Primer on the Current State of Microarray Technologies. Methods in Molecular Biology, 2012, 802, 3-17.	0.9	12
137	Understanding the Melanocyte Distribution in Human Epidermis: An Agent-Based Computational Model Approach. PLoS ONE, 2012, 7, e40377.	2.5	26
138	Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. PLoS ONE, 2012, 7, e48262.	2.5	87
139	CellLineMiner: a knowledge portal for human cell lines. Bioinformation, 2012, 8, 1119-1122.	0.5	0
140	A Novel Photosensitizer for Light-Controlled Gene Silencing. Nucleic Acid Therapeutics, 2011, 21, 359-367.	3.6	6
141	Identifying elemental genomic track types and representing them uniformly. BMC Bioinformatics, 2011, 12, 494.	2.6	20
142	Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer, 2011, 11, 455.	2.6	10
143	Introducing Dynamics into the Field of Biosemiotics. Biosemiotics, 2011, 4, 5-24.	1.4	8
144	Immunological network signatures of cancer progression and survival. BMC Medical Genomics, 2011, 4, 28.	1.5	17

#	Article	IF	Citations
145	The differential disease regulome. BMC Genomics, 2011, 12, 353.	2.8	9
146	CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes and Immunity, 2011, 12, 653-662.	4.1	40
147	Light-Directed Delivery of Nucleic Acids. Methods in Molecular Biology, 2011, 764, 107-121.	0.9	1
148	Abstract 5226:In vivoimaging and molecular characterization of site-specific growth of malignant melanoma: a study of melanoma metastasis in experimental animal models., 2011,,.		0
149	Impact of DNA physical properties on local sequence bias of human mutation. Human Mutation, 2010, 31, 1316-1325.	2.5	9
150	Light-Induced Gene Expression Using Messenger RNA Molecules. Oligonucleotides, 2010, 20, 1-6.	2.7	16
151	Cyclodextrin-Containing Polymer Delivery System for Light-Directed siRNA Gene Silencing. Oligonucleotides, 2010, 20, 175-182.	2.7	25
152	Combining Network Modeling and Gene Expression Microarray Analysis to Explore the Dynamics of Th1 and Th2 Cell Regulation. PLoS Computational Biology, 2010, 6, e1001032.	3.2	21
153	The Genomic HyperBrowser: inferential genomics at the sequence level. Genome Biology, 2010, 11, R121.	9.6	78
154	The disruptive positions in human G-quadruplex motifs are less polymorphic and more conserved than their neutral counterparts. Nucleic Acids Research, 2009, 37, 5749-5756.	14.5	58
155	Segmentation of DNA sequences into twostate regions and melting fork regions. Journal of Physics Condensed Matter, 2009, 21, 034109.	1.8	3
156	Large-scale inference of the point mutational spectrum in human segmental duplications. BMC Genomics, 2009, 10, 43.	2.8	10
157	The mathematics of tanning. BMC Systems Biology, 2009, 3, 60.	3.0	7
158	Non-parametric estimation of reference intervals in small non-Gaussian sample sets. Accreditation and Quality Assurance, 2009, 14, 185-192.	0.8	6
159	Upregulation of stem cell genes in multidrug resistant K562 leukemia cells. Leukemia Research, 2009, 33, 1379-1385.	0.8	23
160	Monitoring B Cell Response to Immunoselected Phage-Displayed Peptides by Microarrays. Methods in Molecular Biology, 2009, 524, 273-285.	0.9	3
161	Methods for quantitation of gene expression. Frontiers in Bioscience - Landmark, 2009, Volume, 552.	3.0	19
162	Activation of NFâ€̂B by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes. International Journal of Cancer, 2008, 123, 1301-1310.	5.1	78

#	Article	IF	Citations
163	Validation of oligoarrays for quantitative exploration of the transcriptome. BMC Genomics, 2008, 9, 258.	2.8	5
164	Evaluation of Various Polyethylenimine Formulations for Light-Controlled Gene Silencing using Small Interfering RNA Molecules. Oligonucleotides, 2008, 18, 123-132.	2.7	29
165	GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data. Genome Biology, 2008, 9, R86.	9.6	14
166	The Majority of Viral-Cellular Fusion Transcripts in Cervical Carcinomas Cotranscribe Cellular Sequences of Known or Predicted Genes. Cancer Research, 2008, 68, 2514-2522.	0.9	74
167	Protein Arrays: A Versatile Toolbox for Target Identification and Monitoring of Patient Immune Responses. , 2007, 360, 335-348.		18
168	Photochemically Induced Gene Silencing Using Small Interfering RNA Molecules in Combination with Lipid Carriers. Oligonucleotides, 2007, 17, 166-173.	2.7	31
169	The Human Genomic Melting Map. PLoS Computational Biology, 2007, 3, e93.	3.2	44
170	Connectivity can be used to identify key genes in DNA microarray data: a study based on gene expression in nasal polyps before and after treatment with glucocorticoids. Acta Oto-Laryngologica, 2007, 127, 1074-1079.	0.9	4
171	Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers. European Journal of Cancer, 2007, 43, 1713-1717.	2.8	106
172	Gene Expression Analysis in Blood Cells in Response to Unmodified and 2′-Modified siRNAs Reveals TLR-dependent and Independent Effects. Journal of Molecular Biology, 2007, 365, 90-108.	4.2	123
173	Comparison of hybridization-based and sequencing-based gene expression technologies on biological replicates. BMC Genomics, 2007, 8, 153.	2.8	61
174	Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate. BMC Genomics, 2007, 8, 273.	2.8	21
175	Photochemically Induced Gene Silencing Using PNA-Peptide Conjugates. Oligonucleotides, 2006, 16, 145-157.	2.7	25
176	Transcriptome changes in a colon adenocarcinoma cell line in response to photochemical treatment as used in photochemical internalisation (PCI). FEBS Letters, 2006, 580, 5739-5746.	2.8	15
177	MUTYH Mutations Do Not Cause HNPCC or Late Onset Familial Colorectal Cancer. Hereditary Cancer in Clinical Practice, 2006, 4, 90.	1.5	6
178	A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nature Biotechnology, 2006, 24, 832-840.	17.5	144
179	Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling. Nucleic Acids Research, 2006, 34, 996-1014.	14.5	116
180	Limitations of mRNA amplification from small-size cell samples. BMC Genomics, 2005, 6, 147.	2.8	35

#	Article	IF	Citations
181	Response of malignant B lymphocytes to ionizing radiation: Gene expression and genotype. International Journal of Cancer, 2005, 115, 935-942.	5.1	21
182	Stitchprofiles.uio.no: analysis of partly melted DNA conformations using stitch profiles. Nucleic Acids Research, 2005, 33, W573-W576.	14.5	19
183	Gene-expression profiling in breast cancer. Lancet, The, 2005, 365, 634-635.	13.7	34
184	Parallel nanoliter detection of cancer markers using polymer microchips. Lab on A Chip, 2005, 5, 416-420.	6.0	91
185	Gene-expression profiling in breast cancer. Lancet, The, 2005, 365, 634-635.	13.7	22
186	The Human Genomic Melting Map. PLoS Computational Biology, 2005, preprint, e93.	3.2	0
187	BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study. British Journal of Cancer, 2004, 91, 1829-1834.	6.4	43
188	Profound influence of microarray scanner characteristics on gene expression ratios: analysis and procedure for correction. BMC Genomics, 2004, 5, 10.	2.8	63
189	Analysis of the humoral immune response to immunoselected phage-displayed peptides by a microarray-based method. Proteomics, 2004, 4, 2572-2582.	2.2	36
190	Double-sided silicon strip detectors: new applications within genomics and proteomics. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 527, 68-72.	1.6	1
191	FigSearch: a figure legend indexing and classification system. Bioinformatics, 2004, 20, 2880-2882.	4.1	25
192	The Detection of Hamster Connexins: A Comparison of Expression Profiles with Wild-Type Mouse and the Cancer-ProneMinMouse. Cell Communication and Adhesion, 2004, 11, 155-171.	1.0	5
193	Determination of Hereditary Mutations in the BRCA1 Gene Using Archived Serum Samples and Capillary Electrophoresis. Analytical Chemistry, 2004, 76, 4406-4409.	6.5	13
194	Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma. Journal of Molecular Diagnostics, 2004, 6, 297-307.	2.8	45
195	Real-Time Nucleic Acid Sequence-Based Amplification in Nanoliter Volumes. Analytical Chemistry, 2004, 76, 9-14.	6.5	122
196	S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clinical and Experimental Metastasis, 2003, 20, 701-711.	3.3	55
197	Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data. BMC Bioinformatics, 2003, 4, 60.	2.6	80
198	Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance. BMC Genomics, 2003, 4, 11.	2.8	66

#	Article	IF	CITATIONS
199	Speed-up of DNA melting algorithm with complete nearest neighbor properties. Biopolymers, 2003, 70, 364-376.	2.4	22
200	MGraph: graphical models for microarray data analysis. Bioinformatics, 2003, 19, 2210-2211.	4.1	29
201	Interferon- $\hat{l}^3$ suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. British Journal of Cancer, 2003, 88, 1995-2001.	6.4	20
202	MArray: analysing single, replicated or reversed microarray experiments. Bioinformatics, 2002, 18, 1139-1140.	4.1	30
203	Analysis of repeatability in spotted cDNA microarrays. Nucleic Acids Research, 2002, 30, 3235-3244.	14.5	49
204	The semantic web and biology. Drug Discovery Today, 2002, 7, 992.	6.4	12
205	Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: Gene expression profiles in bone marrow target cells. International Journal of Cancer, 2002, 97, 28-33.	5.1	15
206	Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. International Journal of Cancer, 2002, 97, 58-63.	5.1	11
207	Associations between gene expressions in breast cancer and patient survival. Human Genetics, 2002, 111, 411-420.	3.8	78
208	CA 125: The End of the Beginning. Tumor Biology, 2001, 22, 345-347.	1.8	11
209	The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective series. European Journal of Cancer, 2001, 37, 1027-1032.	2.8	28
210	Genetic epidemiology of BRCA1 mutations in Norway. European Journal of Cancer, 2001, 37, 2428-2434.	2.8	47
211	Optimization of Hammerhead Ribozymes for the Cleavage of S100A4 (CAPL) mRNA. Oligonucleotides, 2001, 11, 67-75.	4.3	5
212	A literature network of human genes for high-throughput analysis of gene expression. Nature Genetics, 2001, 28, 21-28.	21.4	655
213	Title is missing!. Nature Genetics, 2001, 28, 21-28.	21.4	482
214	Towards Knowledge Discovery from cDNA Microarray Gene Expression Data. Lecture Notes in Computer Science, 2000, , 470-475.	1.3	0
215	BRCA1 1675delA and 1135insA Account for One Third of Norwegian Familial Breast-Ovarian Cancer and Are Associated with Later Disease Onset than Less Frequent Mutations. Disease Markers, 1999, 15, 79-84.	1.3	30
216	Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53. Human Genetics, 1999, 104, 15-22.	3.8	16

#	Article	IF	Citations
217	Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. International Journal of Cancer, 1999, 80, 119-125.	5.1	151
218	Penetrances of BRCA1 1675delA and 1135insA with Respect to Breast Cancer and Ovarian Cancer. American Journal of Human Genetics, 1999, 65, 671-679.	6.2	28
219	Three per cent of Norwegian Ovarian Cancers are caused by BRCA1 1675delA or 1135insA. European Journal of Cancer, 1999, 35, 779-781.	2.8	41
220	S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Research, 1999, 59, 4702-8.	0.9	136
221	Detection of Mutations by Denaturing Gradient Gel Electrophoresis. Current Protocols in Human Genetics, 1998, 17, Unit 7.5.	3.5	2
222	Intracellular metabolism of a 2'-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or asfree ribozyme. A study by capillary electrophoresis. Nucleic Acids Research, 1998, 26, 4241-4248.	14.5	13
223	Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Research, 1997, 25, 151-157.	14.5	301
224	Detection of Mutations by Single-Strand Conformation Polymorphism (SSCP) Analysis and SSCP-Hybrid Methods., 1997, Chapter 7, 7.4.1-7.4.23.		5
225	A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. European Journal of Cancer, 1997, 33, 2390-2392.	2.8	26
226	Ectopic expression of target genes may represent an inherent limitation of RT-PCR assays used for micrometastasis detection: studies on the epithelial glycoprotein geneEGP-2., 1997, 72, 191-196.		40
227	Differential expression patterns of \$100a2, \$100a4 and \$100a6 during progression of human malignant melanoma., 1997, 74, 464-469.		155
228	Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma. International Journal of Cancer, 1997, 74, 464-469.	5.1	7
229	Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. British Journal of Cancer, 1996, 73, 909-916.	6.4	125
230	CDKN2A (p16INK4A) somatic and germline mutations. Human Mutation, 1996, 7, 294-303.	2.5	83
231	Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Research, 1996, 24, 141-146.	14.5	422
232	CDKN2A (p16INK4A) somatic and germline mutations. Human Mutation, 1996, 7, 294-303.	2.5	8
233	Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Research, 1996, 56, 5490-8.	0.9	102
234	Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. British Journal of Cancer, 1995, 72, 393-398.	6.4	97

#	Article	IF	CITATIONS
235	Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Human Mutation, 1995, 5, 48-57.	2.5	56
236	TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes and Cancer, 1995, 14, 71-75.	2.8	154
237	Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Research, 1994, 22, 3551-5.	14.5	646
238	Genome Scanning of Human Breast Carcinomas Using Micro- and Minisatellite Core Probes. Genomics, 1993, 17, 66-75.	2.9	19
239	Detection of DNA variation in cancer. Pharmacogenetics and Genomics, 1992, 2, 317-328.	5.7	13
240	A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas. Cancer Genetics and Cytogenetics, 1992, 64, 178-182.	1.0	10
241	Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 269, 41-53.	1.0	16
242	No alterations in exon 21 of theRBI gene in sarcomas and carcinomas of the breast, colon, and lung. Genes Chromosomes and Cancer, 1992, 5, 97-103.	2.8	10
243	Screening for germ line TP53 mutations in breast cancer patients. Cancer Research, 1992, 52, 3234-6.	0.9	139
244	Chromosome 13 alterations in osteosarcoma cell lines derived from a patient with previous retinoblastoma. Cancer Genetics and Cytogenetics, 1991, 57, 31-40.	1.0	5
245	T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases. Blood, 1991, 77, 2023-2030.	1.4	15
246	Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8405-8409.	7.1	177
247	Analysis of inherited and acquired mutations using PCR and denaturing gradient gel electrophoresis (DGGE). Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1991, 252, 175-176.	0.4	0
248	Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1991, 263, 61.	1.1	3
249	Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1991, 262, 63-71.	1.1	112
250	T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases. Blood, 1991, 77, 2023-2030.	1.4	1
251	Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1988, 202, 77-83.	1.0	39
252	Denaturing gradient gel electrophoresis: A method for separation of DNA fragments differing by single base-pair substitution. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1988, 203, 204.	0.4	0

#	Article	IF	CITATIONS
253	Chromosome 13 instability and esterase D expression in an osteosarcoma cell line. Cancer Genetics and Cytogenetics, 1987, 24, 327-334.	1.0	6
254	Figsearch: using maximum entropy classifier to categorize biological figures. , 0, , .		2